Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12547915 | 1.00 | NPC1 (0.58) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL571211 | 1.00 | NPC1 (0.58) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL3448502 | 0.97 | NPC1 (0.54) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL3448500 | 0.97 | NPC1 (0.54) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL11910976 | 0.91 | NPC1 (0.60) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL14845515 | 0.91 | NPC1 (0.60) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL883239 | 0.90 | NPC1 (0.59) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL19789881 | 0.90 | LMNA (0.60) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL883143 | 0.89 | NPC1 (0.58) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL9611582 | 0.89 | NPC1 (0.58) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2507232-B1 | PROLINE DERIVATIVES | NATIONAL HEALTH RES INST (TW) | 2019-03-20 | — | — | EP | disclosed |
| EP-2513113-B1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3321263-A2 | COMPOUNDS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2018-05-16 | — | — | EP | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3042901-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) | 2018-01-24 | — | — | EP | disclosed |
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2245027-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-7741347-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2146984-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
| WO-2008144380-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | NPC1 65/4885ALDH1A1 1144/4885SMN1; SMN2 4352/4885 |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | NPC1 65/4885ALDH1A1 1144/4885SMN1; SMN2 4352/4885 |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | NPC1 65/4885ALDH1A1 1144/4885SMN1; SMN2 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.